1. Muscarinic receptor drug trihexyphenidyl can alter growth of mesenchymal glioblastoma in vivo
- Author
-
Renfei Du, Ahmed Y. Sanin, Wenjie Shi, Bing Huang, Ann-Christin Nickel, Andres Vargas-Toscano, Shuran Huo, Thomas Nickl-Jockschat, Claudia A. Dumitru, Wei Hu, Siyu Duan, I. Erol Sandalcioglu, Roland S. Croner, Joshua Alcaniz, Wolfgang Walther, Carsten Berndt, and Ulf D. Kahlert
- Subjects
trihexyphenidyl ,glioblastoma ,mesenchymal transformation ,drug repurposing ,cystathionine beta-synthase ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Glioblastoma (GBM) is the most commonly occurring and most aggressive primary brain tumor. Transcriptomics-based tumor subtype classification has established the mesenchymal lineage of GBM (MES-GBM) as cancers with particular aggressive behavior and high levels of therapy resistance. Previously it was show that Trihexyphenidyl (THP), a market approved M1 muscarinic receptor-targeting oral drug can suppress proliferation and survival of GBM stem cells from the classical transcriptomic subtype. In a series of in vitro experiments, this study confirms the therapeutic potential of THP, by effectively suppressing the growth, proliferation and survival of MES-GBM cells with limited effects on non-tumor cells. Transcriptomic profiling of treated cancer cells identified genes and associated metabolic signaling pathways as possible underlying molecular mechanisms responsible for THP-induced effects. In vivo trials of THP in immunocompromised mice carry orthotopic MES-GBMs showed moderate response to the drug. This study further highlights the potential of THP repurposing as an anti-cancer treatment regimen but mode of action and d optimal treatment procedures for in vivo regimens need to be investigated further.
- Published
- 2024
- Full Text
- View/download PDF